DROSTATEX E - Drostanolone Enanthate

Key Benefits of DROSTATEX E: Unmatched muscle hardness: Reduces subcutaneous water, giving muscles a harder, denser, and grainier appearance. This is the most valued effect of Masteron in competitive preparation . Aromatase blockade: Acts as a natural anti-estrogen, inhibiting the aromatase enzyme that converts testosterone to estrogen. This eliminates water retention and gynecomastia, maintaining stable hormonal balance . Prolonged release: The enanthate ester provides a half-life of approximately 8-10 days, allowing administration every 5-7 days with stable plasma levels . This significantly reduces injection frequency compared to the propionate version. Extreme vascularity: Promotes superior vascularity, ideal for competitors seeking a dry and detailed appearance . Muscle mass preservation in deficit: Maintains muscle tissue during severe caloric deficit stages, protecting muscle from catabolism while reducing body fat . Free testosterone increase: By reducing SHBG, it increases free testosterone, which is the most active for protein synthesis and muscle growth . Safe hepatic profile: Not 17-α-alkylated, therefore no known hepatotoxicity . Competition appearance: Provides the dry, hard, and vascularized "look" that judges look for on stage

How does DROSTATEX E work? Drostatex E contains Drostanolone Enanthate USP, an anabolic-androgenic steroid derived from dihydrotestosterone (DHT) with a unique structure that gives it exceptional properties : DHT derivative: Drostanolone is a DHT derivative with the addition of a methyl group at the C-2α position, which increases its anabolic properties and reduces its androgenic effects . Androgen receptor agonist: Binds to the androgen receptor with high affinity, activating signaling pathways that promote protein synthesis and nitrogen retention . Aromatase blockade: Inhibits the aromatase enzyme that converts testosterone to estrogen, reducing estrogen levels and eliminating water retention. This property makes it a natural anti-estrogen . Non-aromatizable: As a DHT derivative, it does not convert to estrogen, meaning it does not cause estrogenic side effects . SHBG reduction: Reduces sex hormone binding globulin levels, increasing the free fraction of testosterone available for protein synthesis . Enanthate pharmacokinetics: The enanthate ester provides prolonged release with a half-life of approximately 8-10 days after intramuscular injection . The addition of the enanthate ester does not alter the anabolic or androgenic effects, but affects the release rate and half-life of the drug . Documented anti-estrogenic effect: Historically, drostanolone was developed for the treatment of breast cancer in women, leveraging its ability to reduce estrogen levels and slow cancer cell growth . Hepatic safety: Not being 17-α-alkylated, it is not associated with hepatotoxicity

Usage Guide for DROSTATEX E: Administration route: Deep and slow intramuscular injection, preferably in the glute (upper outer quadrant) or deltoid. Frequency: Due to its approximately 8-10 day half-life, administration is recommended every 5-7 days to maintain stable plasma levels . Recommended dosage for men: 200 to 400 mg every 5-7 days (1 to 2 mL of DROSTATEX E). Typical dosage for competition preparation ranges from 300-400 mg weekly . Typical cycles of 8 to 10 weeks. Recommended dosage for women: Not recommended for use in women due to high risk of virilization . Recommended cycle: Ideal for advanced cutting protocols, pre-competition, and stage preparation. Excellent for 8-10 week cycles. Stacking: Frequently combined with testosterone (as a base) and other compounds such as Winstrol, Anavar, or Primobolan to enhance definition and muscle hardness effects . Elite athletes like Breon Ansley use Masteron alongside Testosterone and Primobolan in their competition preparation . Post-cycle therapy (PCT): PCT should be started approximately 2-3 weeks after the last injection due to the compound's prolonged release. Typical 4-week protocol. Precautions and monitoring: Periodic monitoring of lipid profile, blood pressure, and hematocrit levels is recommended during the cycle . Anti-doping warning: Drostanolone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition) . Documented cases include Marion Jones, who was stripped of her Olympic medals for drostanolone us

Composition of DROSTATEX E: Active Ingredient: Drostanolone Enanthate USP 200 mg per mL. High-purity compound with USP pharmaceutical grade and ≥98% purity . Chemical name: (5α)-2α-methyl-3-oxo-4,5-dihydrotestosterone heptanoate . Molecular formula: C₂₇H₄₄O₃ . Molecular weight: 416.64 g/mol. CAS Number: 13425-31-5 . Vehicle: Pharmaceutical-grade sesame oil (Sesamum indicum), selected for its low viscosity and excellent tolerance profile. Preservative: Benzyl alcohol (1-2%) as a bacteriostatic agent, ensuring product stability and sterility. Presentation: 1 mL ampoules with 200 mg/mL concentration (10 ampoules per box). Total of 200 mg of Drostanolone Enanthate per ampoule. Appearance: Clear pale yellow oily solution. Classification: Schedule III controlled substance in the United States . Certification: Manufactured under USP (United States Pharmacopeia) and GMP (Good Manufacturing Practices) standards. Quality control: Purity and potency testing performed by certified independent laboratories using high-performance liquid chromatography (HPLC) and mass spectrometry. Purity: ≥98% purity, guaranteeing maximum quality and consistency in each batch . Storage: Store at controlled room temperature 20°-25°C (68°-77°F), in a dry place protected from light. Do not freeze.

Onset time and expected results: Onset time: Effects begin to be noticeable between 7 and 14 days of continuous use. The enanthate ester provides sustained release with stable plasma concentrations. Results at 2-4 weeks: Increased muscle hardness, better definition, greater vascularity, and sensation of muscle density. Visible reduction in water retention. Results at 4-6 weeks: Significant improvement in body composition, fat loss, and muscle mass maintenance. Drier, harder, and more detailed physique . Results at 6-8 weeks: Complete competitive appearance: hard, dry, vascularized, and grainy muscles. Superior muscle quality ready for the stage . Expected results (8-10 week cycle at 300-400 mg weekly): Lean muscle mass: Maintenance of mass (+0-1 kg in men) Strength increase in compound exercises: +5-10% Body fat reduction: 5-8% Muscle hardness and definition: Excellent - The compound is known for providing the "grainy" appearance characteristic of competitors Water retention: Minimal to none - Anti-estrogenic effect Estrogenic side effects: Absent

Clinical research and laboratory testing: Origin and development: Drostanolone was originally developed in the 1970s by Syntex under the name Masteril, for the treatment of advanced breast cancer in women. Its antitumor mechanism is related to the reduction or competitive inhibition of prolactin or estrogen receptors . Medical history: Drostanolone was FDA-approved for the treatment of inoperable breast cancer in climacteric women, a designation that was withdrawn in 2005 . Enanthate development: The enanthate version was developed to provide a longer-acting formulation, allowing for less frequent dosing and sustained therapeutic effect . Molecular structure: The crystal structure of drostanolone enanthate was determined by X-ray diffraction in a 2024 study, confirming its molecular identity and purity . Pharmacokinetic profile: Schänzer et al. (1996) studies documented a half-life of approximately 8-10 days for drostanolone enanthate, with slow release from the injection site and hepatic metabolism . Metabolites and detection: Drostanolone metabolite detection can be performed up to 24 days after administration via liquid-liquid extraction . Use in sport: Its use in sport has been documented in multiple cases, including the case of Marion Jones, who was stripped of her Olympic medals for drostanolone use . Drostanolone is regularly confiscated by anti-doping authorities, such as the NADA raid in India in 2026 where prohibited substances including drostanolone were seized. Safety profile: Non-hepatotoxic: Not being 17-α-alkylated, it presents no known risk of hepatotoxicity Non-aromatizable: Does not convert to estrogen, eliminating estrogenic effects Cardiovascular profile: Drostanolone may affect lipid profile and increase blood pressure, although studies suggest lower impact than other compounds Virilization in women: High risk of virilizing effects 3rd party testing: Our batches are subjected to purity and potency testing by certified independent laboratories using: High-performance liquid chromatography (HPLC) for purity Mass spectrometry for molecular identification Sterility and bacterial endotoxin testing Certifications: Manufactured under GMP (Good Manufacturing Practices) standards USP quality control (United States Pharmacopeia) Stability and shelf-life testing (24 months) Heavy metals and contaminant analysis Anti-doping warning: Drostanolone is included in the WADA 2025-2026 Prohibited List as S1.1 Anabolic Androgenic Steroids, prohibited at all times (in and out of competition)